Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
HUMAN PLASMA PROTEIN >90% GAMMA GLOBULIN
Baxter Healthcare Limited
0.5 g/30 m
Pdr+Solv for soln for Inf
1998-05-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gammagard S/D. Human normal immunoglobulin for intravenous administration. Powder and solvent for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENT Human Normal Immunoglobulin G (IgG) QUANTITATIVE COMPOSITION Human Normal Immunoglobulin for Intravenous Administration, Gammagard S/D, may be reconstituted with solvent [Water for Injections] to a 5 % (50 mg/ml) solution or a 10 % (100 mg/ml) solution of protein of which at least 90% is gamma globulin. Contains less than 3 µ g/ml of IgA for a 5% solution. For a full list of excipients see section 6.1. IGG SUBCLASSES Distribution of IgG subclasses: IgG 1 ≥ 56.9% IgG 2 ≥ 16.0% IgG 3 ≥ 3.3% IgG 4 ≥ 0.3% 3 PHARMACEUTICAL FORM Powder and solvent for solution for infusion. p.H. of reconstituted product is 6.4 – 7.2. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS REPLACEMENT THERAPY: Primary immunodeficiency syndromes (PID) : Congenital agammaglobulinaemia and hypogammaglobulinaemia Common variable immunodeficiencies. Severe combined immunodeficiencies. Wiskott Aldrich syndrome IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/03/2011_ _CRN 2079437_ _page number: 1_ Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections Children with congenital AIDS and recurrent infections. IMMUNOMODULATORY EFFECT Idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery to correct the platelet count. Allogeneic bone marrow transplantation. Kawasaki syndrome. Guillain-Barre disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY The dose and dosage regimen is dependent on the indi Read the complete document